The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO GI 2026 | Biological insights and breakthroughs in HER2+ lower GI cancers
Ramon Salazar, MD, PhD, Institut Catala D’Oncologia, Barcelona, Spain, discusses biological insights and emerging breakthroughs in HER2-positive lower gastrointestinal (GI) cancer. Dr Salazar also highlights that RAS and BRAF are important drivers in acquired resistance, hence HER2-targeting agents tend to be more effective in tumors also with mutations in these molecules. New antibody-drug conjugates (ADCs) could help overcome resistance due to bystander effects, but they still require tumors to be HER2-positive for efficacy. This interview took place at the European Society for Medical Oncology (ESMO) Gastrointestinal Cancer 2026 Congress in Munich, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
